TriPath Imaging, Inc. Its FocalPoint slide profiler utilizes visual intelligence technology to increase accuracy in distinguishing between normal Pap smears and those that have the highest likelihood of abnormality. TriPath Oncology develops and manages the market introduction of molecular diagnostic and pharmaceutical products and services for treating cervical, breast, ovarian, and prostate cancer.
View Article. In recent months, deficiencies in forensic pathology have made news in both the United States and Canada. In a story released February 5,on CaliforniaWatch.
TriPath Imaging has agreed to use its reasonable best efforts to hold a special meeting of its shareholders, as promptly as practicable, for the purpose of considering the acquisition and to file a proxy statement and solicit proxies in favor of its approval. TriPath Imaging develops, manufactures, markets and sells innovative solutions to improve the clinical management of cancer, including detection, diagnosis, staging and treatment. SinceBD has been collaborating with the company to identify bio-markers for various cancer diagnostics.
Skip to Content. Use the menu to see other pages. This section explains the types of treatments that are the standard of care for early-stage and locally advanced breast cancer.
Please complete this secure form. The information you provide will help us assist you as efficiently as possible. A representative will contact you within one to two business days to help you schedule an appointment.
Find information and resources for current and returning patients. Learn about clinical trials at MD Anderson and search our database for open studies. The Lyda Hill Cancer Prevention Center provides cancer risk assessment, screening and diagnostic services.
Skip to main content. Published: Aug 15, The proposal arose after a review by TriPath Imaging of potential strategic opportunities.
In recent years, the application of genomic and proteomic technologies to the problem of breast cancer prognosis and the prediction of therapy response have begun to yield encouraging results. Independent studies employing transcriptional profiling of primary breast cancer specimens using DNA microarrays have identified gene expression profiles that correlate with clinical outcome in primary breast biopsy specimens. Recent advances in microarray technology have demonstrated reproducibility, making clinical applications more achievable.